HeraMED

HeraMED Overview

HeraMED is a technology start-up company developing connected pregnancy monitoring solutions for home use. HeraMEDs hardware solutions and software applications are focused on fetal well-being and parental assurance. The companys HeraBEAT is a medically accurate and scientifically optimized smartphone-based fetal heartbeat monitor for home use. HeraBEAT allows expectant mothers to monitor the fetal heartbeat anytime, anywhere and enables the seamless sharing of fetal vital sign data with medical professionals. HeraBEAT integrates technology and professional accuracy with a simple and straightforward user interface and a distinctive design, resulting in a safe, reliable, and affordable solution. HeraBEAT is BSI certified with the CE mark for medical devices. It received 510(k) clearance from the FDA in November 2019. The companys HeraCARE is a digital platform enabling a new model of care for women throughout pregnancy. HeraMEDs future products include the EchoBEAT line of home-based pregnancy monitoring devices and ORION, an AI-powered pregnancy monitoring system. Developed in cooperation with the Mayo Clinic, Orion is trained to detect precursors that can indicate possible pregnancy complications before they become a problem.

Cumulative Funding Raised Over Time ($)

Latest News

Aug 31, 2025 · finance.yahoo.com

growth-negative

HeraMED First Half 2025 Earnings: AU$0.003 loss per share (vs AU$0.009 loss in 1H 2024)

HeraMED reported a revenue of AU$139.5k, which is down by 23% from the first half of 2024. The company also reported a net loss of AU$2.26 million, although this loss has narrowed by 30% compared to the same period last year. The loss per share has improved from AU$0.009 to AU$0.003. Despite these financial challenges, HeraMED shares have increased by 10% over the past week. The article also mentions that there are five warning signs for HeraMED, four of which are significant. The analysis provided is based on historical data and analyst forecasts, and it is not intended as financial advice.

Mar 4, 2025 · finance.yahoo.com

growth-negative

HeraMED Full Year 2024 Earnings: AU$1.03 loss per share (vs AU$0.025 loss in FY 2023)

HeraMED reported a revenue of AU$364.3k, which is a 38% decrease from FY 2023. The company also reported a net loss of AU$5.49m, which is a 17% improvement from the previous fiscal year. The loss per share stands at AU$1.03. HeraMEDs shares have declined by 15% over the past week. The article highlights that there are six warning signs associated with HeraMED, five of which are concerning. The analysis provided is based on historical data and analyst forecasts and does not constitute financial advice.

Mar 16, 2021 · stockhead.com.au

growth-positive

Leading scientific publication backs HeraMED's foetal heartbeat monitor - Stockhead

The official publication of the American College of Obstetricians and Gynecologists has endorsed HeraMEDs foetal monitoring device. The endorsement is expected to increase awareness of the HeraCARE platform and HeraBEAT device, leading to new partnership opportunities. HeraMED is currently collaborating with Mayo Clinic and Sheba Medical Centre. The article highlights the accuracy and ease of use of the HeraBEAT device, positioning it as a viable alternative for medical professionals in pre-natal care.

Partners

Feb 8, 2021 · themarketherald-com-au.cdn.ampproject.org

growth-positive

Israel's largest hospital to pilot HeraMED (ASX:HMD) pregnancy tech

HeraMED will have its pregnancy monitoring solutions tested in a pilot study at Israels largest hospital, the Sheba Medical Centre. The pilot study will be conducted in multiple stages, with the first stage focusing on using the HeraBEAT smart pregnancy monitor in the dedicated pregnancy COVID-19 unit. The second stage will explore additional uses beyond COVID-19, such as high-risk pregnancies. HeraMED CEO is excited to partner with Sheba and looks forward to potential commercial partnership. The Director of the Sheba Womens Health Innovation Centre is also enthusiastic about the partnership and aims to provide premium maternal care using cutting-edge technologies.

Customers

Dec 16, 2020 · techinvest.online

growth-positive

HeraMED partners with Teleperinatal to launch HeraCARE and HeraBEAT - TechInvest Magazine Online

HeraMED Limited has signed a Letter of Intent with Teleperinatal to deploy its maternal care app and smart foetal HR monitor. The initial pilot will be followed by a formal commercial agreement. Teleperinatal provides a maternity benefits program for employers, and the partnership aims to reduce the cost of pregnancy care. The program will be sold directly to employers, with a focus on Fortune 500 Companies. Several contracts have already been secured, and it is estimated that over 10,000 pregnant women will be under management by the end of 2021. The partnership will involve the deployment of the HeraCARE mobile app and the sale of the HeraBEAT device. Teleperinatal will pay a license fee for the HeraCARE platform and offer the HeraBEAT device to its users for an additional fee. The partnership is part of HeraMEDs US market entry strategy.

PartnersCustomers

Funding

Team Members

6

Employees: 11-50

Web & Social Links

Locations

Meir Ariel Street 6, Netanya, Israel

23-25 Hunter Street, Sydney NSW, Australia

Photos & Videos

4 item(s)

HeraMED Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info